200 related articles for article (PubMed ID: 29599310)
1. Antitumor Activity of Novel Bone-seeking, α-emitting
Juzeniene A; Bernoulli J; Suominen M; Halleen J; Larsen RH
Anticancer Res; 2018 Apr; 38(4):1947-1955. PubMed ID: 29599310
[TBL] [Abstract][Full Text] [Related]
2. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model.
Henriksen G; Breistøl K; Bruland ØS; Fodstad Ø; Larsen RH
Cancer Res; 2002 Jun; 62(11):3120-5. PubMed ID: 12036923
[TBL] [Abstract][Full Text] [Related]
3. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride.
Pacilio M; Ventroni G; De Vincentis G; Cassano B; Pellegrini R; Di Castro E; Frantellizzi V; Follacchio GA; Garkavaya T; Lorenzon L; Ialongo P; Pani R; Mango L
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):21-33. PubMed ID: 26266887
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer.
Parker CC; Pascoe S; Chodacki A; O'Sullivan JM; Germá JR; O'Bryan-Tear CG; Haider T; Hoskin P
Eur Urol; 2013 Feb; 63(2):189-97. PubMed ID: 23000088
[TBL] [Abstract][Full Text] [Related]
5. Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis.
Abou DS; Ulmert D; Doucet M; Hobbs RF; Riddle RC; Thorek DL
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26683407
[TBL] [Abstract][Full Text] [Related]
6. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases.
Nilsson S; Larsen RH; Fosså SD; Balteskard L; Borch KW; Westlin JE; Salberg G; Bruland OS
Clin Cancer Res; 2005 Jun; 11(12):4451-9. PubMed ID: 15958630
[TBL] [Abstract][Full Text] [Related]
7. In situ Generated
Stenberg VY; Juzeniene A; Bruland ØS; Larsen RH
Curr Radiopharm; 2020; 13(2):130-141. PubMed ID: 32389119
[TBL] [Abstract][Full Text] [Related]
8. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?
Bruland ØS; Nilsson S; Fisher DR; Larsen RH
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6250s-6257s. PubMed ID: 17062709
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer.
Ueno NT; Tahara RK; Fujii T; Reuben JM; Gao H; Saigal B; Lucci A; Iwase T; Ibrahim NK; Damodaran S; Shen Y; Liu DD; Hortobagyi GN; Tripathy D; Lim B; Chasen BA
Cancer Med; 2020 Feb; 9(3):1025-1032. PubMed ID: 31849202
[TBL] [Abstract][Full Text] [Related]
10. Calcium Carbonate Microparticles as Carriers of
Li RG; Napoli E; Jorstad IS; Bønsdorff TB; Juzeniene A; Bruland ØS; Larsen RH; Westrøm S
Curr Radiopharm; 2021; 14(2):145-153. PubMed ID: 33261548
[TBL] [Abstract][Full Text] [Related]
11. Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases.
Hindorf C; Chittenden S; Aksnes AK; Parker C; Flux GD
Nucl Med Commun; 2012 Jul; 33(7):726-32. PubMed ID: 22513884
[TBL] [Abstract][Full Text] [Related]
12. Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models.
Suominen MI; Fagerlund KM; Rissanen JP; Konkol YM; Morko JP; Peng Z; Alhoniemi EJ; Laine SK; Corey E; Mumberg D; Ziegelbauer K; Käkönen SM; Halleen JM; Vessella RL; Scholz A
Clin Cancer Res; 2017 Aug; 23(15):4335-4346. PubMed ID: 28364014
[No Abstract] [Full Text] [Related]
13. Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1: α therapy with 223Ra-dichloride.
Pandit-Taskar N; Larson SM; Carrasquillo JA
J Nucl Med; 2014 Feb; 55(2):268-74. PubMed ID: 24343987
[TBL] [Abstract][Full Text] [Related]
14. Dual targeting with
Juzeniene A; Stenberg VY; Bruland ØS; Revheim ME; Larsen RH
Front Med (Lausanne); 2022; 9():1051825. PubMed ID: 36733936
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Metastatic Bone Disease and the Emerging Role of Radium-223.
Coleman R
Semin Nucl Med; 2016 Mar; 46(2):99-104. PubMed ID: 26897713
[TBL] [Abstract][Full Text] [Related]
16. Preparation of
Westrøm S; Generalov R; Bønsdorff TB; Larsen RH
Nucl Med Biol; 2017 Aug; 51():1-9. PubMed ID: 28486098
[TBL] [Abstract][Full Text] [Related]
17. Targeted alpha therapy using Radium-223: From physics to biological effects.
Marques IA; Neves AR; Abrantes AM; Pires AS; Tavares-da-Silva E; Figueiredo A; Botelho MF
Cancer Treat Rev; 2018 Jul; 68():47-54. PubMed ID: 29859504
[TBL] [Abstract][Full Text] [Related]
18. Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells.
Nakata A; Tsujimura T; Sugihara A; Okamura H; Iwasaki T; Shinkai K; Iwata N; Kakishita E; Akedo H; Terada N
Anticancer Res; 1999; 19(5B):4131-8. PubMed ID: 10628364
[TBL] [Abstract][Full Text] [Related]
19. Dose-Dependent Growth Delay of Breast Cancer Xenografts in the Bone Marrow of Mice Treated with
Leung CN; Canter BS; Rajon D; Bäck TA; Fritton JC; Azzam EI; Howell RW
J Nucl Med; 2020 Jan; 61(1):89-95. PubMed ID: 31519805
[TBL] [Abstract][Full Text] [Related]
20. Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation protection.
Cheetham PJ; Petrylak DP
Oncology (Williston Park); 2012 Apr; 26(4):330-7, 341. PubMed ID: 22655525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
